Association between Plasma Fibrinogen Levels and Mortality in Acute-on-Chronic Hepatitis B Liver Failure
Table 1
Clinical characteristics of enrolled participants.
Variables
Control (171)
CHB (173)
AoCLF (169)
value
Female/male
37/134
35/138
32/137
0.825
Age (year)
46.43 ± 8.80
44.47 ± 9.82
46.08 ± 12.90
0.190
HBsAg positive
0
173
169
—
HBeAg positive
0
92
78
—
HBV DNA positive
0
173
169
—
TBIL (μmol/L)
12 (6–49)
23 (5–430)
209 (10–947)*#
<0.001
ALT (U/L)
17 (7–48)
65 (9–1838)
65 (10–3686)#
<0.001
ALB (g/L)
46.5 (40–55.1)
37.8 (24.4–52.4)
32.4 (20.4–46.2)*#
<0.001
Cr (μmol/L)
75 (38–100)
66 (29–154)
65 (23–760)
0.004
PT (S)
10.8 (9.4–12.7)
13.0 (10.1–24.1)
22.2 (11.1–120)*#
<0.001
Fibrinogen (g/L)
2.58 ± 0.49
1.88 ± 0.56
1.39 ± 0.58#*
<0.001
INR
0.94 (0.82–1.10)
1.14 (0.88–2.05)
1.92 (0.97–10.4)*#
<0.001
D-dimer (μg/L FEU)
150 (2–510)
337 (30–5550)
1892 (150–43858)*#
<0.001
MELD score
6.06 (0.17–20.29)
18.88 (3.98–57.17)
<0.001
Decompensation (yes/no)
0/173
88/81*
—
Mortality (yes/no)
0/173
60/109*
—
CHB, chronic hepatitis B; AoCLF, acute-on-chronic hepatitis B liver failure; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; TBIL, total bilirubin; ALT, alanine aminotransferase; ALB, albumin; Cr, creatinine; PT, prothrombin time; INR, international normalized ratio; FEU, fibrinogen equivalent units; MELD score, the model for end-stage liver disease score. value: comparison among these three groups. versus the control group. *P < 0.05 versus the CHB group.